secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001493152-24-048285
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 reverses insulin resistance to near pre-diabetes in zebrafish T2D study
--------------------------------------------------------------------------------

- Telomir-1 restored glucose homeostasis, reducing HOMA-IR values and improving oral glucose tolerance in zebrafish model.
- Dose-dependent normalization of blood glucose levels observed; insulin resistance reversed to near pre-diabetes levels.
- Novel mechanism targets iron metabolism to address oxidative stress and beta-cell damage, root causes of Type 2 diabetes.
- Treated models showed increased survival rates, reinforcing therapeutic potential of Telomir-1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315224048285/0001493152-24-048285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315224048285/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-048285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer